Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes

References

• American Diabetes Association. Standards of medical care in diabetes – 2009. Diabetes Care 2009;32(Suppl 1):S13-61
   PubMed Web of Science ®Google Scholar
• Deedwania P, Srikanth S. Diabetes and vascular disease. Expert Rev Cardiovasc Ther 2008;6:127-38
   PubMedGoogle Scholar
• Garber AJ, Handelsman Y, Einhorn D, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract 2008;14:933-46
   PubMedGoogle Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
   Google Scholar
• Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97
   Google Scholar
• Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-7
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med 2007;24:137-44
   PubMed Web of Science ®Google Scholar
• Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44
   PubMed Web of Science ®Google Scholar
• Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Pogue J, Mann JF, et al. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 2005;48:1749-55
   PubMed Web of Science ®Google Scholar
• Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421-31
   PubMed Web of Science ®Google Scholar
• Cefalu WT. Glycemic targets and cardiovascular disease. N Engl J Med 2008;358:2633-5
   PubMed Web of Science ®Google Scholar
• Reasner CA. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors. J Cardiovasc Pharmacol 2008;52:136-44
   PubMed Web of Science ®Google Scholar
• Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008;31:811-22
   PubMed Web of Science ®Google Scholar
• Adiels M, Olofsson SO, Taskinen MR, et al. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:1225-36
   PubMed Web of Science ®Google Scholar
• Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 1998;316:823-8
   PubMed Web of Science ®Google Scholar
• Lee ET, Howard BV, Wang W, et al. Prediction of coronary heart disease in a population with high prevalence of diabetes and albuminuria: the Strong Heart Study. Circulation 2006;113:2897-905
   PubMed Web of Science ®Google Scholar
• Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
   PubMed Web of Science ®Google Scholar
• Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation 1998;98:2513-19
   PubMed Web of Science ®Google Scholar
• Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999;159:2661-7
   PubMed Web of Science ®Google Scholar
• Liu J, Sempos C, Donahue RP, et al. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care 2005;28:1916-21
   PubMed Web of Science ®Google Scholar
• Sacks FM. The apolipoprotein story. Atheroscler Suppl 2006;7:23-7
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Co. Glucophage (metformin hydrochloride tablets) prescribing information
   Google Scholar
• Carter D, Howlett HC, Wiernsperger NF, et al. Effects of metformin on bile salt transport by monolayers of human intestinal Caco-2 cells. Diabetes Obes Metab 2002;4:424-7
   PubMed Web of Science ®Google Scholar
• Carter D, Howlett HC, Wiernsperger NF, et al. Differential effects of metformin on bile salt absorption from the jejunum and ileum. Diabetes Obes Metab 2003;5:120-5
   PubMed Web of Science ®Google Scholar
• Scarpello JH, Hodgson E, Howlett HC. Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabet Med 1998;15:651-6
   PubMed Web of Science ®Google Scholar
• Bays HE, Goldberg RB, Truitt KE, et al. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 2008;168:1975-83
   PubMed Web of Science ®Google Scholar
• Fonseca VA, Rosenstock J, Wang AC, et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008;31:1479-84
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Fonseca VA, Truitt KE, et al. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008;168:1531-40
   PubMed Web of Science ®Google Scholar
• Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007;29:74-83
   PubMed Web of Science ®Google Scholar
• Fonseca VA, Goldfine AB, Abby SL, Jones MR, Nagendran S. Response to colesevelam HCl in patients with type 2 diabetes. National Lipid Association Annual Scientific Session, Seattle, WA, 2008.
   Google Scholar
• Danaei G, Lawes CM, Vander Hoorn S, et al. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet 2006;368:1651-9
   PubMed Web of Science ®Google Scholar
• Meigs JB, Nathan DM, Wilson PW, et al. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study. Ann Intern Med 1998;128:524-33
   PubMed Web of Science ®Google Scholar
• DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?. Diabetes Care 2003;26:688-96
   PubMed Web of Science ®Google Scholar
• Saydah SH, Loria CM, Eberhardt MS, et al. Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care 2001;24:447-53
   PubMed Web of Science ®Google Scholar
• Levitan EB, Song Y, Ford ES, et al. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004;164:2147-55
   PubMed Web of Science ®Google Scholar
• Eldin WS, Emara M, Shoker A. Prediabetes: a must to recognise disease state. Int J Clin Pract 2008;62:642-8
   PubMed Web of Science ®Google Scholar
• Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007;334:299
   PubMed Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
   PubMed Web of Science ®Google Scholar
• Abby S, Jones M, Jin X, et al. Colesevelam HCl effects in patients with impaired fasting glucose. 5th Annual World Congress on the Insulin Resistance Syndrome, Boston, MA, 2007
   Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2007;30(Suppl 1):S42-7
   PubMedGoogle Scholar
• World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Geneva, 1999. WHO/NCD/NCS 99.2
   Google Scholar
• Stokes ME, Davis CS, Koch GG. Categorical Data Analysis using the SAS System, 2nd edn. Cary, NC: SAS Publishing, 2000
   Google Scholar
• Davidson MH. Global risk management in patients with type 2 diabetes mellitus. Am J Cardiol 2007;99:41-50B
   Web of Science ®Google Scholar
• Kirk JK, Huber KR, Clinch CR. Attainment of goals from national guidelines among persons with type 2 diabetes: a cohort study in an academic family medicine setting. N C Med J 2005;66:415-19
   PubMedGoogle Scholar
• Spann SJ, Nutting PA, Galliher JM, et al. Management of type 2 diabetes in the primary care setting: a practice-based research network study. Ann Fam Med 2006;4:23-31
   PubMed Web of Science ®Google Scholar
• Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-42
   PubMed Web of Science ®Google Scholar
• Ford ES, Li C, Little RR, Mokdad AH. Trends in A1C concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004. Diabetes Care 2008;31:102-4
   PubMed Web of Science ®Google Scholar
• Kennedy AG, MacLean CD, Littenberg B, et al. The challenge of achieving national cholesterol goals in patients with diabetes. Diabetes Care 2005;28:1029-34
   PubMed Web of Science ®Google Scholar
• Bays HE, Goldberg RB. The ‘forgotten’ bile acid sequestrants: is now a good time to remember?. Am J Ther 2007;14:567-80
   PubMed Web of Science ®Google Scholar
• Goldfine AB. Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway. Curr Opin Cardiol 2008;23:502-11
   PubMed Web of Science ®Google Scholar
• Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008;358:2630-3
   PubMed Web of Science ®Google Scholar
• Haffner SM. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol 2003;92:18-26J
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Staels B, Kuipers F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 2007;67:1383-92
   PubMed Web of Science ®Google Scholar
• Jacobson TA, Armani A, McKenney JM, et al. Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol 2007;99:47-55C
   PubMed Web of Science ®Google Scholar
• Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001;110:352-60
   PubMed Web of Science ®Google Scholar
• Hunninghake D, Insull W Jr, Toth P, et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001;158:407-16
   PubMed Web of Science ®Google Scholar
• Devaraj S, Autret B, Jialal I. Effects of colesevelam hydrochloride (WelChol) on biomarkers of inflammation in patients with mild hypercholesterolemia. Am J Cardiol 2006;98:641-3
   PubMed Web of Science ®Google Scholar
• Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007;30:753-9
   PubMed Web of Science ®Google Scholar
• Thomas C, Pellicciari R, Pruzanski M, et al. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008;7:678-93
   PubMed Web of Science ®Google Scholar